Does the media prefer AVCT or OXB?

In the previous week, Avacta Group had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.22 beat Avacta Group's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AVCT or SLN?

Avacta Group presently has a consensus price target of GBX 99, suggesting a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer AVCT or HZD?

Avacta Group currently has a consensus target price of GBX 99, suggesting a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor PRTC or AVCT?

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.34 beat Avacta Group's score of 0.00 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AVCT or ARIX?

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Avacta Group is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Avacta Group (AVCT) Competitors

GBX 73 +4.10 (+5.95%)

As of 09/11/2026 12:29 PM Eastern

Compare

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

Should you buy Avacta Group stock or one of its competitors? Avacta Group's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avacta Group compare to Oxford Biomedica?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Avacta Group currently has a consensus price target of GBX 99, suggesting a potential upside of 35.62%. Oxford Biomedica has a consensus price target of GBX 580.85, suggesting a potential upside of 30.82%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,026.90	-£30.08M	-£9.66	N/A
Oxford Biomedica	£168.74M	3.19	-£143.51M	-£26.92	N/A

In the previous week, Avacta Group had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.22 beat Avacta Group's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 43.3% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Avacta Group beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Silence Therapeutics?

Avacta Group (LON:AVCT) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Silence Therapeutics has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,026.90	-£30.08M	-£9.66	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

In the previous week, Avacta Group had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Silence Therapeutics	Neutral

Avacta Group presently has a consensus price target of GBX 99, suggesting a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.1% of Avacta Group shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Silence Therapeutics	N/A	N/A	N/A

Summary

Avacta Group beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Avacta Group (LON:AVCT) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Avacta Group currently has a consensus target price of GBX 99, suggesting a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,026.90	-£30.08M	-£9.66	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

3.1% of Avacta Group shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

In the previous week, Avacta Group had 2 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 2 mentions for Avacta Group and 0 mentions for Horizon Discovery Group plc (HZD.L). Avacta Group's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Summary

Avacta Group beats Horizon Discovery Group plc (HZD.L) on 7 of the 12 factors compared between the two stocks.

How does Avacta Group compare to PureTech Health?

PureTech Health (LON:PRTC) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.34 beat Avacta Group's score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avacta Group has lower revenue, but higher earnings than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.83	-£91.86M	-£46.00	N/A
Avacta Group	£113K	3,026.90	-£30.08M	-£9.66	N/A

PureTech Health presently has a consensus target price of GBX 508, indicating a potential upside of 325.46%. Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 35.62%. Given PureTech Health's higher probable upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

30.7% of PureTech Health shares are owned by institutional investors. Comparatively, 3.1% of Avacta Group shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by company insiders. Comparatively, 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PureTech Health has a beta of 0.771, meaning that its share price is 23% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Summary

PureTech Health beats Avacta Group on 8 of the 14 factors compared between the two stocks.

How does Avacta Group compare to Arix Bioscience?

Avacta Group (LON:AVCT) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 20.7% of Arix Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arix Bioscience has a net margin of 105.64% compared to Avacta Group's net margin of -33,961.06%. Arix Bioscience's return on equity of 6.41% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Arix Bioscience	105.64%	6.41%	2.18%

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 35.62%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Avacta Group is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Avacta Group had 2 more articles in the media than Arix Bioscience. MarketBeat recorded 2 mentions for Avacta Group and 0 mentions for Arix Bioscience. Avacta Group's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Arix Bioscience	Neutral

Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,026.90	-£30.08M	-£9.66	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Summary

Arix Bioscience beats Avacta Group on 8 of the 14 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVCT vs. The Competition

Export

Metric	Avacta Group	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£342.04M	£3.86B	£7.15B	£2.87B
Dividend Yield	3.97%	3.63%	2.56%	6.22%
P/E Ratio	-7.56	14.11	272.98	366.83
Price / Sales	3,026.90	1,415.79	642.14	83,599.70
Price / Cash	15.00	106.68	77.04	27.89
Price / Book	4.95	15.13	10.33	6.33
Net Income	-£30.08M	-£22.82M	£3.49B	£5.89B
7 Day Performance	8.15%	-4.31%	-3.33%	-0.69%
1 Month Performance	12.31%	0.00%	-0.40%	0.18%
1 Year Performance	32.73%	40.67%	19.15%	20.03%

Avacta Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVCT Avacta Group	1.7334 of 5 stars	GBX 73 +6.0%	GBX 99 +35.6%	+32.7%	£342.04M	£113K	N/A	120
OXB Oxford Biomedica	2.5197 of 5 stars	GBX 435 +2.0%	GBX 580.85 +33.5%	-26.0%	£526.51M	£168.74M	N/A	891	News Coverage
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	2.9804 of 5 stars	GBX 121.60 -3.5%	GBX 508 +317.8%	+4.6%	£296.00M	£4.66M	N/A	300	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AVCT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avacta Group (AVCT) Competitors

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

How does Avacta Group compare to Oxford Biomedica?

Summary

How does Avacta Group compare to Silence Therapeutics?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Avacta Group compare to PureTech Health?

Summary

How does Avacta Group compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avacta Group (AVCT) Competitors

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

How does Avacta Group compare to Oxford Biomedica?

Do analysts rate AVCT or OXB?

Is AVCT or OXB more profitable?

Which has more volatility & risk, AVCT or OXB?

Which has stronger valuation and earnings, AVCT or OXB?

Does the media prefer AVCT or OXB?

Do institutionals & insiders believe in AVCT or OXB?

Summary

How does Avacta Group compare to Silence Therapeutics?

Which has better valuation & earnings, AVCT or SLN?

Does the media prefer AVCT or SLN?

Do analysts prefer AVCT or SLN?

Do insiders & institutionals hold more shares of AVCT or SLN?

Is AVCT or SLN more profitable?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Do analysts prefer AVCT or HZD?

Which has higher valuation and earnings, AVCT or HZD?

Do insiders and institutionals hold more shares of AVCT or HZD?

Is AVCT or HZD more profitable?

Does the media refer more to AVCT or HZD?

Summary

How does Avacta Group compare to PureTech Health?

Does the media favor PRTC or AVCT?

Which has higher earnings and valuation, PRTC or AVCT?

Do analysts rate PRTC or AVCT?

Do institutionals and insiders believe in PRTC or AVCT?

Which has more risk & volatility, PRTC or AVCT?

Is PRTC or AVCT more profitable?

Summary

How does Avacta Group compare to Arix Bioscience?

Do insiders & institutionals have more ownership in AVCT or ARIX?

Is AVCT or ARIX more profitable?

Do analysts recommend AVCT or ARIX?

Does the media prefer AVCT or ARIX?

Which has more volatility & risk, AVCT or ARIX?

Which has better earnings and valuation, AVCT or ARIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools